Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Redwood Wealth Management Group LLC

Redwood Wealth Management Group LLC increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 497 shares of the biopharmaceutical company’s stock after buying an additional 20 shares during the quarter. Redwood Wealth Management Group LLC’s holdings in Regeneron Pharmaceuticals were worth $354,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of REGN. Centaurus Financial Inc. acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $118,000. Czech National Bank increased its holdings in Regeneron Pharmaceuticals by 7.0% in the 3rd quarter. Czech National Bank now owns 21,617 shares of the biopharmaceutical company’s stock worth $22,725,000 after buying an additional 1,405 shares during the period. GAMMA Investing LLC grew its stake in shares of Regeneron Pharmaceuticals by 32.6% during the 3rd quarter. GAMMA Investing LLC now owns 1,436 shares of the biopharmaceutical company’s stock worth $1,510,000 after purchasing an additional 353 shares during the period. Miracle Mile Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 12.6% during the 3rd quarter. Miracle Mile Advisors LLC now owns 2,562 shares of the biopharmaceutical company’s stock worth $2,693,000 after purchasing an additional 286 shares during the period. Finally, Greenfield Savings Bank increased its holdings in shares of Regeneron Pharmaceuticals by 28.6% during the 3rd quarter. Greenfield Savings Bank now owns 612 shares of the biopharmaceutical company’s stock valued at $643,000 after purchasing an additional 136 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 4.5 %

Shares of NASDAQ REGN opened at $697.05 on Wednesday. The company has a 50 day simple moving average of $719.16 and a 200-day simple moving average of $918.90. The company has a market capitalization of $76.60 billion, a P/E ratio of 17.25, a P/E/G ratio of 1.60 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $11.86 EPS. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.75 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.50%.

Wall Street Analysts Forecast Growth

REGN has been the subject of several analyst reports. Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Bernstein Bank lowered their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday. JPMorgan Chase & Co. lowered their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. TD Cowen lowered their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Bank of America reissued an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $983.65.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.